GlassScriptPhysician profile
Somwail Rasla
NPI 1942614011
$1,815.28
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,532 · 2020: $284.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $230.66 | 2019 | |
| Novartis Pharmaceuticals Corporation | $221.36 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $204.41 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $191.58 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $141.57 | 2019 | |
| Amgen INC. | $131.59 | 2019-2020 | |
| Z-Medica, LLC | $124.45 | 2019-2020 | |
| Lantheus Medical Imaging, INC. | $116.94 | 2019-2020 | |
| Astellas Pharma US INC | $114.42 | 2019-2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $85.16 | 2019-2020 | |
| Medtronic Vascular, INC. | $84.37 | 2019-2020 | |
| Vifor Pharma, INC. | $59.46 | 2019 | |
| Amarin Pharma, INC. | $51.50 | 2019-2020 | |
| Boston Scientific Corporation | $25.00 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.25 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $13.56 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Somwail Rasla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.